File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Dendritic cells-mediated CTLs targeting hepatocellular carcinoma stem cells

TitleDendritic cells-mediated CTLs targeting hepatocellular carcinoma stem cells
Authors
KeywordsCancer stem cells
Dendritic cells
Hepatocellular carcinoma
Immunotherapy
Issue Date2010
PublisherLandes Bioscience. The Journal's web site is located at http://www.landesbioscience.com/journals/cbt/index.php
Citation
Cancer Biology And Therapy, 2010, v. 10 n. 4, p. 368-375 How to Cite?
AbstractImmunotherapy, especially using dendritic cells (DCs)-based vaccine, appears promising in the treatment of hepatocellular carcinoma (HCC) following surgery. However, the therapeutic efficacy of current DC vaccines loaded with HCC antigen is limited in clinical practice. One important reason might be that the DC vaccines for the treatment of HCC were not aimed at targeting the hepatocellular carcinoma cancer stem cells (HCCCSCs). Therefore, establishing an immunotherapy to kill HCC stem cells could be a novel therapeutic strategy. In this study, we have developed an immunotherapy to target CD133 + HCC cells in the treatment of HCC. This study had three main findings; (1) CD133 +HCC cells RNA loaded DCs could induce special CD8 + cytotoxic T lymphocytes (CD133 +Huh7-CTLs) response against CD133 + Huh7 cells in vitro. (2) Huh7 cells-induced tumor growth in vivo was effectively inhibited by CD133 +Huh7-CTLs. (3) the great inhibition potential of CD133 +Huh7-CTLs to Huh7-induced tumor growth might not be only associated with anti-tumor cytokines such as IFNγ, but also to CD133 +Huh7-DCs induced specific CTLs. This study shows an experimental proof that CD133 +HCC cells RNA loaded DC vaccine has potential in treating HCC and may provide a new therapy for clinical post operative adjuvant therapy in future. © 2010 Landes Bioscience.
Persistent Identifierhttp://hdl.handle.net/10722/150833
ISSN
2015 Impact Factor: 2.921
2015 SCImago Journal Rankings: 1.297
ISI Accession Number ID
Funding AgencyGrant Number
National Natural Science Foundation of Chinau0772002
Funding Information:

Project supported by the Joint Funds of the National Natural Science Foundation of China (Grant No. u0772002 to Jianchuan Xia and Qizhou Lian).

References

 

DC FieldValueLanguage
dc.contributor.authorSun, JCen_HK
dc.contributor.authorPan, Ken_HK
dc.contributor.authorChen, MSen_HK
dc.contributor.authorWang, QJen_HK
dc.contributor.authorWang, Hen_HK
dc.contributor.authorMa, HQen_HK
dc.contributor.authorLi, YQen_HK
dc.contributor.authorLiang, XTen_HK
dc.contributor.authorLi, JJen_HK
dc.contributor.authorZhao, JJen_HK
dc.contributor.authorChen, YBen_HK
dc.contributor.authorPang, XHen_HK
dc.contributor.authorLiu, WLen_HK
dc.contributor.authorCao, Yen_HK
dc.contributor.authorGuan, XYen_HK
dc.contributor.authorLian, QZen_HK
dc.contributor.authorXia, JCen_HK
dc.date.accessioned2012-06-26T06:11:42Z-
dc.date.available2012-06-26T06:11:42Z-
dc.date.issued2010en_HK
dc.identifier.citationCancer Biology And Therapy, 2010, v. 10 n. 4, p. 368-375en_HK
dc.identifier.issn1538-4047en_HK
dc.identifier.urihttp://hdl.handle.net/10722/150833-
dc.description.abstractImmunotherapy, especially using dendritic cells (DCs)-based vaccine, appears promising in the treatment of hepatocellular carcinoma (HCC) following surgery. However, the therapeutic efficacy of current DC vaccines loaded with HCC antigen is limited in clinical practice. One important reason might be that the DC vaccines for the treatment of HCC were not aimed at targeting the hepatocellular carcinoma cancer stem cells (HCCCSCs). Therefore, establishing an immunotherapy to kill HCC stem cells could be a novel therapeutic strategy. In this study, we have developed an immunotherapy to target CD133 + HCC cells in the treatment of HCC. This study had three main findings; (1) CD133 +HCC cells RNA loaded DCs could induce special CD8 + cytotoxic T lymphocytes (CD133 +Huh7-CTLs) response against CD133 + Huh7 cells in vitro. (2) Huh7 cells-induced tumor growth in vivo was effectively inhibited by CD133 +Huh7-CTLs. (3) the great inhibition potential of CD133 +Huh7-CTLs to Huh7-induced tumor growth might not be only associated with anti-tumor cytokines such as IFNγ, but also to CD133 +Huh7-DCs induced specific CTLs. This study shows an experimental proof that CD133 +HCC cells RNA loaded DC vaccine has potential in treating HCC and may provide a new therapy for clinical post operative adjuvant therapy in future. © 2010 Landes Bioscience.en_HK
dc.languageengen_US
dc.publisherLandes Bioscience. The Journal's web site is located at http://www.landesbioscience.com/journals/cbt/index.phpen_HK
dc.relation.ispartofCancer Biology and Therapyen_HK
dc.subjectCancer stem cellsen_HK
dc.subjectDendritic cellsen_HK
dc.subjectHepatocellular carcinomaen_HK
dc.subjectImmunotherapyen_HK
dc.subject.meshAnimalsen_US
dc.subject.meshAntigens, Cd - Immunologyen_US
dc.subject.meshCancer Vaccines - Immunology - Therapeutic Useen_US
dc.subject.meshCarcinoma, Hepatocellular - Immunology - Therapyen_US
dc.subject.meshCell Line, Tumoren_US
dc.subject.meshDendritic Cells - Immunologyen_US
dc.subject.meshGene Expressionen_US
dc.subject.meshGlycoproteins - Immunologyen_US
dc.subject.meshHumansen_US
dc.subject.meshImmunotherapy - Methodsen_US
dc.subject.meshInterferon-Gamma - Metabolismen_US
dc.subject.meshInterleukin-12 - Metabolismen_US
dc.subject.meshInterleukin-7 - Metabolismen_US
dc.subject.meshMiceen_US
dc.subject.meshMice, Inbred Balb Cen_US
dc.subject.meshMice, Nudeen_US
dc.subject.meshNeoplastic Stem Cells - Immunologyen_US
dc.subject.meshPeptides - Immunologyen_US
dc.subject.meshRnaen_US
dc.subject.meshT-Lymphocytes, Cytotoxic - Immunologyen_US
dc.titleDendritic cells-mediated CTLs targeting hepatocellular carcinoma stem cellsen_HK
dc.typeArticleen_HK
dc.identifier.emailGuan, XY:xyguan@hkucc.hku.hken_HK
dc.identifier.emailLian, QZ:qzlian@hkucc.hku.hken_HK
dc.identifier.authorityGuan, XY=rp00454en_HK
dc.identifier.authorityLian, QZ=rp00267en_HK
dc.description.naturelink_to_OA_fulltexten_US
dc.identifier.doi10.4161/cbt.10.4.12440en_HK
dc.identifier.pmid20581468-
dc.identifier.scopuseid_2-s2.0-77957120092en_HK
dc.identifier.hkuros204426-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-77957120092&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume10en_HK
dc.identifier.issue4en_HK
dc.identifier.spage368en_HK
dc.identifier.epage375en_HK
dc.identifier.isiWOS:000281005700010-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridSun, JC=34868948200en_HK
dc.identifier.scopusauthoridPan, K=23098129100en_HK
dc.identifier.scopusauthoridChen, MS=24333976200en_HK
dc.identifier.scopusauthoridWang, QJ=36560867400en_HK
dc.identifier.scopusauthoridWang, H=16647722500en_HK
dc.identifier.scopusauthoridMa, HQ=35484962700en_HK
dc.identifier.scopusauthoridLi, YQ=36120668800en_HK
dc.identifier.scopusauthoridLiang, XT=25925200800en_HK
dc.identifier.scopusauthoridLi, JJ=26633932100en_HK
dc.identifier.scopusauthoridZhao, JJ=36505540900en_HK
dc.identifier.scopusauthoridChen, YB=36503427000en_HK
dc.identifier.scopusauthoridPang, XH=36131882400en_HK
dc.identifier.scopusauthoridLiu, WL=37665509200en_HK
dc.identifier.scopusauthoridCao, Y=35344387700en_HK
dc.identifier.scopusauthoridGuan, XY=7201463221en_HK
dc.identifier.scopusauthoridLian, QZ=7003399023en_HK
dc.identifier.scopusauthoridXia, JC=7402327355en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats